Dr. Frantz Lerebours, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 22812 Linden Blvd, Cambria Heights, NY 11411 Phone: 718-528-3206 Fax: 212-939-2759 |
News Archive
Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share.
Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.
Postnova Analytics reports on the extended data available through integrating its AF2000 MultiFlow Flow Field-Flow Fractionation (FFF) platform with its SC2000 modular multi-detector Size Exclusion chromatography (SEC) system.
ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.
Scientists from the Institute of Molecular and Cell Biology, a research institute under the Agency for Science, Technology and Research, have discovered that obese individuals lack a protein that is essential for regulating blood glucose levels, causing them to face higher risks of developing diabetes.
› Verified 1 days ago